TrialContemporary clinical trials2015

A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.

Nolan A Wages et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.